FDA Breakthrough Designation | CheckRare.com
Sen Zhuang, MD, PhD of Janssen Pharmaceuticals explains what a Breakthrough Therapy Designation means in terms of drug and clinical trial development.
Related Articles
Urea Cycle Disorders: Overview and Developing Novel Therapies
Yuri Maricich, MD, CMO of CAMP4 Therapeutics, provides an overview of urea cycle disorders (UCDs) and discusses developing novel therapies.
Hematologic Malignancies and Clinical Trial Participation: A Shared Decision-Making Approach
John Kuruvilla, MD, explores best practices for discussing possible clinical trial participation with patients with hematologic malignancies
Newly Approved Treatment Targets Underlying Cause of IgG4-Related Disease
Arezou Khosroshahi, MD, discusses the approval of Uplizna (inebilizumab-cdon) for treatment of immunoglobulin G4-related disease (IgG4-RD).
FDA Approves Treatment for Pheochromocytoma or Paraganglioma
The U.S. FDA has approved belzutifan for patients with locally advanced, unresectable or metastatic pheochromocytoma or paraganglioma.
Neuroblastoma
Neuroblastoma is a rare childhood cancer characterized by a neuroendocrine tumor originating in neuroblasts or neural crest progenitor cells.
Positive Safety and Efficacy Data for Intrathecal Administration of Gene Therapy for SMA
Norman Putzki, MD, Novartis, discusses positive safety and efficacy data for OAV101 IT, an investigational gene therapy for SMA.
Navigating Diagnosis and Treatment for Primary Biliary Cholangitis: The Integral Role of the Patient Voice
Dr. Sonal Kumar, discusses the integral role of the patient voice in navigating disease progression and determining an individualized care plan for people living with…
Neuroblastoma: Evan Foundation
Gavin Lindberg details his family’s experience with neuroblastoma, provides advice to families, and discusses the EVAN Foundation.
Tenosynovial Giant Cell Tumor (TGCT)
Tenosynovial giant cell tumor (TGCT) is a rare benign tumor involving the joint synovium, bursae, and tendon sheath.
Global Genes’ Patient and Advocate Initiatives
Daniel DeFabio, Global Genes and rare disease father, discusses Global Genes’ patient and advocate initiatives.